Is NGNE or SPRB more profitable?

Neurogene's return on equity of -44.36% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -44.36% -40.61% Spruce Biosciences N/A -118.22% -88.36%

Does the media refer more to NGNE or SPRB?

In the previous week, Spruce Biosciences had 2 more articles in the media than Neurogene. MarketBeat recorded 9 mentions for Spruce Biosciences and 7 mentions for Neurogene. Neurogene's average media sentiment score of 0.53 beat Spruce Biosciences' score of -0.26 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Is CAPR or SPRB more profitable?

Capricor Therapeutics' return on equity of -53.27% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -53.27% -42.10% Spruce Biosciences N/A -118.22% -88.36%

Does the media refer more to CAPR or SPRB?

In the previous week, Capricor Therapeutics had 13 more articles in the media than Spruce Biosciences. MarketBeat recorded 22 mentions for Capricor Therapeutics and 9 mentions for Spruce Biosciences. Capricor Therapeutics' average media sentiment score of 0.24 beat Spruce Biosciences' score of -0.26 indicating that Capricor Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Spruce Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Is SPRB or DMAC more profitable?

DiaMedica Therapeutics' return on equity of -77.76% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -118.22% -88.36% DiaMedica Therapeutics N/A -77.76% -69.43%

Does the media prefer SPRB or DMAC?

In the previous week, Spruce Biosciences had 6 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 9 mentions for Spruce Biosciences and 3 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.53 beat Spruce Biosciences' score of -0.26 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SPRB or CBIO more profitable?

Crescent Biopharma's return on equity of -101.50% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -118.22% -88.36% Crescent Biopharma N/A -101.50% -86.86%

Does the media prefer SPRB or CBIO?

In the previous week, Spruce Biosciences had 7 more articles in the media than Crescent Biopharma. MarketBeat recorded 9 mentions for Spruce Biosciences and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.72 beat Spruce Biosciences' score of -0.26 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Crescent Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SPRB or RGNX?

In the previous week, REGENXBIO had 11 more articles in the media than Spruce Biosciences. MarketBeat recorded 20 mentions for REGENXBIO and 9 mentions for Spruce Biosciences. REGENXBIO's average media sentiment score of 0.05 beat Spruce Biosciences' score of -0.26 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral REGENXBIO 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Spruce Biosciences (SPRB) Competitors

$46.20 -0.47 (-1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$46.33 +0.13 (+0.28%)

As of 07:56 PM Eastern

Compare

SPRB vs. NGNE, CAPR, DMAC, CBIO, and RGNX

Should you buy Spruce Biosciences stock or one of its competitors? Spruce Biosciences's main competitors and comparable companies include Neurogene (NGNE), Capricor Therapeutics (CAPR), DiaMedica Therapeutics (DMAC), Crescent Biopharma (CBIO), and REGENXBIO (RGNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Spruce Biosciences compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

In the previous week, Spruce Biosciences had 2 more articles in the media than Neurogene. MarketBeat recorded 9 mentions for Spruce Biosciences and 7 mentions for Neurogene. Neurogene's average media sentiment score of 0.53 beat Spruce Biosciences' score of -0.26 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Neurogene's return on equity of -44.36% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-44.36%	-40.61%
Spruce Biosciences	N/A	-118.22%	-88.36%

Neurogene has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.57, indicating that its stock price is 257% more volatile than the broader market.

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Spruce Biosciences has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	558.68	-$90.35M	-$5.03	N/A
Spruce Biosciences	$4.91M	27.00	-$38.97M	-$33.71	N/A

Neurogene presently has a consensus target price of $79.57, indicating a potential upside of 217.02%. Spruce Biosciences has a consensus target price of $158.33, indicating a potential upside of 242.71%. Given Spruce Biosciences' higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Spruce Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Neurogene beats Spruce Biosciences on 8 of the 15 factors compared between the two stocks.

How does Spruce Biosciences compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

In the previous week, Capricor Therapeutics had 13 more articles in the media than Spruce Biosciences. MarketBeat recorded 22 mentions for Capricor Therapeutics and 9 mentions for Spruce Biosciences. Capricor Therapeutics' average media sentiment score of 0.24 beat Spruce Biosciences' score of -0.26 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Spruce Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Capricor Therapeutics currently has a consensus price target of $29.77, indicating a potential upside of 165.35%. Spruce Biosciences has a consensus price target of $158.33, indicating a potential upside of 242.71%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Spruce Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Capricor Therapeutics' return on equity of -53.27% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-53.27%	-42.10%
Spruce Biosciences	N/A	-118.22%	-88.36%

Spruce Biosciences has lower revenue, but higher earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	29.29	-$105.04M	-$2.45	N/A
Spruce Biosciences	$4.91M	27.00	-$38.97M	-$33.71	N/A

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Capricor Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.57, suggesting that its share price is 257% more volatile than the broader market.

Summary

Capricor Therapeutics beats Spruce Biosciences on 8 of the 14 factors compared between the two stocks.

How does Spruce Biosciences compare to DiaMedica Therapeutics?

Spruce Biosciences (NASDAQ:SPRB) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

DiaMedica Therapeutics has lower revenue, but higher earnings than Spruce Biosciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	27.00	-$38.97M	-$33.71	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Spruce Biosciences presently has a consensus price target of $158.33, indicating a potential upside of 242.71%. DiaMedica Therapeutics has a consensus price target of $12.00, indicating a potential upside of 24.22%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Spruce Biosciences is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Spruce Biosciences had 6 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 9 mentions for Spruce Biosciences and 3 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.53 beat Spruce Biosciences' score of -0.26 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DiaMedica Therapeutics' return on equity of -77.76% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-118.22%	-88.36%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by company insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Spruce Biosciences has a beta of 3.57, indicating that its share price is 257% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Summary

Spruce Biosciences beats DiaMedica Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Spruce Biosciences compare to Crescent Biopharma?

Spruce Biosciences (NASDAQ:SPRB) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Crescent Biopharma's return on equity of -101.50% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-118.22%	-88.36%
Crescent Biopharma	N/A	-101.50%	-86.86%

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Spruce Biosciences has a beta of 3.57, meaning that its share price is 257% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Spruce Biosciences presently has a consensus target price of $158.33, indicating a potential upside of 242.71%. Crescent Biopharma has a consensus target price of $33.00, indicating a potential upside of 123.58%. Given Spruce Biosciences' higher possible upside, equities research analysts clearly believe Spruce Biosciences is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Spruce Biosciences has higher earnings, but lower revenue than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	27.00	-$38.97M	-$33.71	N/A
Crescent Biopharma	$10.84M	50.57	-$153.94M	-$6.72	N/A

In the previous week, Spruce Biosciences had 7 more articles in the media than Crescent Biopharma. MarketBeat recorded 9 mentions for Spruce Biosciences and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.72 beat Spruce Biosciences' score of -0.26 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Crescent Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Crescent Biopharma beats Spruce Biosciences on 9 of the 15 factors compared between the two stocks.

How does Spruce Biosciences compare to REGENXBIO?

Spruce Biosciences (NASDAQ:SPRB) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, REGENXBIO had 11 more articles in the media than Spruce Biosciences. MarketBeat recorded 20 mentions for REGENXBIO and 9 mentions for Spruce Biosciences. REGENXBIO's average media sentiment score of 0.05 beat Spruce Biosciences' score of -0.26 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
REGENXBIO	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 14.2% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Spruce Biosciences has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	27.00	-$38.97M	-$33.71	N/A
REGENXBIO	$170.44M	3.29	-$193.88M	-$3.21	N/A

Spruce Biosciences has a net margin of 0.00% compared to REGENXBIO's net margin of -113.85%. Spruce Biosciences' return on equity of -118.22% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-118.22%	-88.36%
REGENXBIO	-113.85%	-203.98%	-42.54%

Spruce Biosciences has a beta of 3.57, indicating that its stock price is 257% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Spruce Biosciences presently has a consensus price target of $158.33, indicating a potential upside of 242.71%. REGENXBIO has a consensus price target of $23.18, indicating a potential upside of 173.69%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Spruce Biosciences is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

Spruce Biosciences beats REGENXBIO on 10 of the 17 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRB vs. The Competition

Export

Metric	Spruce Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$134.12M	$4.16B	$7.89B	$12.02B
Dividend Yield	N/A	3.63%	2.45%	4.45%
P/E Ratio	-1.37	34.52	34.39	28.04
Price / Sales	27.00	16.88	8.90	5.91
Price / Cash	N/A	26.63	22.08	22.50
Price / Book	2.00	4.22	4.45	3.80
Net Income	-$38.97M	-$22.76M	$3.50B	$390.04M
7 Day Performance	-0.88%	-1.08%	-0.97%	-1.10%
1 Month Performance	4.88%	-6.80%	-4.07%	-6.19%
1 Year Performance	-58.99%	1.72%	2.04%	-5.75%

Spruce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRB Spruce Biosciences	2.4209 of 5 stars	$46.20 -1.0%	$158.33 +242.7%	-59.6%	$134.12M	$4.91M	N/A	8	News Coverage Earnings Report
NGNE Neurogene	2.231 of 5 stars	$26.08 +1.7%	$80.29 +207.9%	-10.7%	$525.15M	N/A	N/A	131	News Coverage Earnings Report Upcoming Earnings Analyst Forecast Gap Up
CAPR Capricor Therapeutics	2.9957 of 5 stars	$8.97 +4.3%	$30.25 +237.2%	+59.5%	$521.23M	$22.27M	N/A	231	Trending News Earnings Report Analyst Upgrade Gap Up
DMAC DiaMedica Therapeutics	1.9094 of 5 stars	$9.54 +5.5%	$12.00 +25.9%	+59.6%	$516.65M	N/A	N/A	35
CBIO Crescent Biopharma	3.1872 of 5 stars	$13.73 +6.1%	$33.00 +140.4%	+6.2%	$509.99M	$11.88M	N/A	44	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRB) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spruce Biosciences (SPRB) Competitors

SPRB vs. NGNE, CAPR, DMAC, CBIO, and RGNX

How does Spruce Biosciences compare to Neurogene?

Summary

How does Spruce Biosciences compare to Capricor Therapeutics?

Summary

How does Spruce Biosciences compare to DiaMedica Therapeutics?

Summary

How does Spruce Biosciences compare to Crescent Biopharma?

Summary

How does Spruce Biosciences compare to REGENXBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spruce Biosciences (SPRB) Competitors

SPRB vs. NGNE, CAPR, DMAC, CBIO, and RGNX

How does Spruce Biosciences compare to Neurogene?

Does the media refer more to NGNE or SPRB?

Is NGNE or SPRB more profitable?

Which has more volatility and risk, NGNE or SPRB?

Do insiders & institutionals have more ownership in NGNE or SPRB?

Which has higher earnings and valuation, NGNE or SPRB?

Do analysts recommend NGNE or SPRB?

Summary

How does Spruce Biosciences compare to Capricor Therapeutics?

Does the media refer more to CAPR or SPRB?

Do analysts prefer CAPR or SPRB?

Is CAPR or SPRB more profitable?

Which has higher earnings and valuation, CAPR or SPRB?

Do institutionals and insiders believe in CAPR or SPRB?

Which has more volatility and risk, CAPR or SPRB?

Summary

How does Spruce Biosciences compare to DiaMedica Therapeutics?

Which has better earnings & valuation, SPRB or DMAC?

Do analysts recommend SPRB or DMAC?

Does the media prefer SPRB or DMAC?

Is SPRB or DMAC more profitable?

Do insiders & institutionals believe in SPRB or DMAC?

Which has more volatility and risk, SPRB or DMAC?

Summary

How does Spruce Biosciences compare to Crescent Biopharma?

Is SPRB or CBIO more profitable?

Do institutionals and insiders have more ownership in SPRB or CBIO?

Which has more risk and volatility, SPRB or CBIO?

Do analysts rate SPRB or CBIO?

Which has preferable earnings & valuation, SPRB or CBIO?

Does the media prefer SPRB or CBIO?

Summary

How does Spruce Biosciences compare to REGENXBIO?

Does the media prefer SPRB or RGNX?

Do institutionals & insiders believe in SPRB or RGNX?

Which has stronger earnings and valuation, SPRB or RGNX?

Is SPRB or RGNX more profitable?

Which has more volatility & risk, SPRB or RGNX?

Do analysts recommend SPRB or RGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools